Abbott Laboratories released positive six-month clinical trial data showing high success and safety rates for its TactiFlex Duo Ablation Catheter in treating complex atrial fibrillation (AFib). The FlexPulse study found 87% of patients remained free from arrhythmias, with 98.3% experiencing no major safety issues. Additional trials on Abbott's pacing and defibrillation technologies showed strong performance, including a 99% success rate in left bundle branch area pacing and 100% defibrillation success. These results support Abbott's position in the cardiac device market and may drive further adoption of its technologies.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
